TD Private Client Wealth LLC Acquires 8,393 Shares of Baxter International Inc. (NYSE:BAX)

TD Private Client Wealth LLC lifted its stake in shares of Baxter International Inc. (NYSE:BAX - Free Report) by 21.5% in the first quarter, according to its most recent filing with the SEC. The fund owned 47,438 shares of the medical instruments supplier's stock after acquiring an additional 8,393 shares during the period. TD Private Client Wealth LLC's holdings in Baxter International were worth $1,624,000 as of its most recent SEC filing.

A number of other hedge funds also recently made changes to their positions in BAX. CoreFirst Bank & Trust bought a new stake in shares of Baxter International during the 4th quarter worth $26,000. Rossby Financial LCC bought a new stake in shares of Baxter International during the 1st quarter worth $29,000. MassMutual Private Wealth & Trust FSB lifted its holdings in shares of Baxter International by 48.1% during the 1st quarter. MassMutual Private Wealth & Trust FSB now owns 2,021 shares of the medical instruments supplier's stock worth $69,000 after acquiring an additional 656 shares during the last quarter. Farther Finance Advisors LLC lifted its holdings in shares of Baxter International by 61.2% during the 4th quarter. Farther Finance Advisors LLC now owns 4,060 shares of the medical instruments supplier's stock worth $118,000 after acquiring an additional 1,541 shares during the last quarter. Finally, Bruce G. Allen Investments LLC lifted its holdings in shares of Baxter International by 35.2% during the 1st quarter. Bruce G. Allen Investments LLC now owns 3,546 shares of the medical instruments supplier's stock worth $121,000 after acquiring an additional 924 shares during the last quarter. 90.19% of the stock is owned by institutional investors.

Baxter International Price Performance

Shares of BAX stock traded up $0.51 on Thursday, hitting $30.32. 1,499,439 shares of the stock traded hands, compared to its average volume of 4,447,219. The firm has a market cap of $15.56 billion, a price-to-earnings ratio of -27.57, a PEG ratio of 0.90 and a beta of 0.61. Baxter International Inc. has a 52 week low of $26.25 and a 52 week high of $40.49. The firm has a 50 day simple moving average of $30.61 and a two-hundred day simple moving average of $31.24. The company has a debt-to-equity ratio of 1.33, a current ratio of 2.02 and a quick ratio of 1.40.

Baxter International (NYSE:BAX - Get Free Report) last announced its quarterly earnings data on Thursday, May 1st. The medical instruments supplier reported $0.62 EPS for the quarter, beating the consensus estimate of $0.48 by $0.14. The firm had revenue of $2.63 billion for the quarter, compared to the consensus estimate of $2.59 billion. Baxter International had a negative net margin of 4.71% and a positive return on equity of 17.24%. The company's revenue was up 5.4% on a year-over-year basis. During the same period last year, the firm earned $0.65 EPS. As a group, equities research analysts predict that Baxter International Inc. will post 2.48 earnings per share for the current fiscal year.

Baxter International Announces Dividend

The firm also recently disclosed a quarterly dividend, which was paid on Tuesday, July 1st. Shareholders of record on Friday, May 30th were paid a $0.17 dividend. The ex-dividend date of this dividend was Friday, May 30th. This represents a $0.68 dividend on an annualized basis and a dividend yield of 2.24%. Baxter International's payout ratio is currently -61.82%.

Wall Street Analysts Forecast Growth

BAX has been the subject of a number of research analyst reports. Wells Fargo & Company dropped their price objective on shares of Baxter International from $36.00 to $33.00 and set an "equal weight" rating for the company in a report on Friday, May 2nd. Morgan Stanley decreased their target price on shares of Baxter International from $30.00 to $28.00 and set an "underweight" rating on the stock in a research report on Monday, May 5th. Wall Street Zen upgraded shares of Baxter International from a "hold" rating to a "buy" rating in a research report on Sunday, June 22nd. Evercore ISI decreased their target price on shares of Baxter International from $44.00 to $42.00 and set an "outperform" rating on the stock in a research report on Tuesday. Finally, Citigroup decreased their target price on shares of Baxter International from $34.00 to $32.00 and set a "neutral" rating on the stock in a research report on Wednesday. One analyst has rated the stock with a sell rating, three have issued a hold rating and six have assigned a buy rating to the company's stock. According to data from MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus price target of $36.50.

Baxter International Profile

Baxter International Inc, through its subsidiaries, develops and provides a portfolio of healthcare products worldwide. The company operates through four segments: Medical Products and Therapies, Healthcare Systems and Technologies, Pharmaceuticals, and Kidney Care. The company offers sterile intravenous (IV) solutions; infusion systems and devices; parenteral nutrition therapies; generic injectable pharmaceuticals; surgical hemostat and sealant products, advanced surgical equipment; smart bed systems; patient monitoring and diagnostic technologies; and respiratory health devices, as well as advanced equipment for the surgical space, including surgical video technologies, precision positioning devices, and other accessories.